A comparison between adjuvant and delivering functions of iron oxide and calcium phosphate nanoparticles, using a model protein against .

Tahereh Goudarzi, Morteza Abkar, Mahdi Fasihi-Ramandi, Mohammadsaleh Peikar, Zahra Zamanzadeh
Author Information
  1. Tahereh Goudarzi: Department of Genetics, Faculty of Biological Sciences and Technology, Shahid Ashrafi Esfahani University, Isfahan, Iran. ORCID
  2. Morteza Abkar: Department of Genetics, Faculty of Biological Sciences and Technology, Shahid Ashrafi Esfahani University, Isfahan, Iran. ORCID
  3. Mahdi Fasihi-Ramandi: Molecular Biology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran. ORCID
  4. Mohammadsaleh Peikar: Hematology/Oncology Division, Department of Internal Medicine, Isfahan University of Medical Science, Isfahan, Iran. ORCID
  5. Zahra Zamanzadeh: Department of Genetics, Faculty of Biological Sciences and Technology, Shahid Ashrafi Esfahani University, Isfahan, Iran. ORCID

Abstract

Purpose: Calcium phosphate (CaP) and iron oxide (IO) nanoparticles (NPs) are promising adjuvants and delivery systems for vaccination. Furthermore, it has been shown that the chimeric antigen TF/Bp26/Omp31 (TBO) is a good candidate for stimulating protection against virulent . Our aim in the present study was to compare the roles of CaP and IO NPs for induction of the immune response and protection against 16M by using the TBO antigen as a model protein.
Materials and Methods: The gene was expressed in the bacterial host and was evaluated by SDS-PAGE and western blot. The recombinant TBO was loaded onto CaP (CaP/TBO) and IO (IO/TBO) NPs. CaP/TBO and IO/TBO NPs were administered subcutaneously.
Results: Antibody levels showed that immunization with both CaP/TBO and IO/TBO NPs stimulated mixed Th1-Th2 immune responses. In addition, immunized mice were challenged with a virulent strain of 16M. Immunized mice with CaP/TBO NPs showed a higher degree of protection than vaccinated animals with IO/TBO NPs.
Conclusion: Altogether, our results indicated that the CaP NPs are a potent adjuvant and delivery system for subcutaneously administered antigens.

Keywords

References

  1. FASEB J. 2013 Mar;27(3):1153-66 [PMID: 23195035]
  2. Microb Pathog. 2019 Sep;134:103601 [PMID: 31212035]
  3. Galen Med J. 2019 Oct 29;8:e1296 [PMID: 34466489]
  4. Biomaterials. 2019 Dec;223:119464 [PMID: 31525691]
  5. Vet Q. 2021 Jan 1;41(1):61-88 [PMID: 33353489]
  6. Microorganisms. 2022 Oct 11;10(10): [PMID: 36296279]
  7. Vaccines (Basel). 2020 Mar 01;8(1): [PMID: 32121590]
  8. Basic Clin Neurosci. 2019 Mar-Apr;10(2):157-164 [PMID: 31031902]
  9. Mol Pharm. 2018 May 7;15(5):1791-1799 [PMID: 29570298]
  10. J Biotechnol. 2020 Feb 20;310:89-96 [PMID: 32017955]
  11. Int J Nanomedicine. 2020 May 29;15:3877-3886 [PMID: 32581535]
  12. Immunol Lett. 2019 Mar;207:28-35 [PMID: 30707922]
  13. Clin Exp Vaccine Res. 2023 Oct;12(4):304-312 [PMID: 38025913]
  14. Pediatr Rev. 2018 Apr;39(4):222-224 [PMID: 29610436]
  15. PLoS Negl Trop Dis. 2022 Jul 26;16(7):e0010635 [PMID: 35881641]
  16. J Neurol Sci. 2021 Jan 15;420:117280 [PMID: 33358192]
  17. Am J Pathol. 2015 Jun;185(6):1505-17 [PMID: 25892682]
  18. Recent Pat Antiinfect Drug Discov. 2013 Apr;8(1):27-33 [PMID: 22934672]
  19. Pol J Microbiol. 2018 Jun 30;67(2):151-161 [PMID: 30015453]
  20. J Immunol Methods. 2022 Jan;500:113172 [PMID: 34673003]
  21. AAPS PharmSciTech. 2019 Oct 7;20(8):315 [PMID: 31591662]
  22. Clin Diagn Lab Immunol. 2000 Nov;7(6):899-903 [PMID: 11063495]
  23. Infect Dis (Lond). 2019 May;51(5):321-333 [PMID: 30773082]
  24. Vaccines (Basel). 2020 Nov 03;8(4): [PMID: 33153189]
  25. Microb Pathog. 2021 Apr;153:104764 [PMID: 33548480]
  26. Parasitol Res. 2017 Feb;116(2):609-616 [PMID: 27909791]
  27. Clin Exp Vaccine Res. 2015 Jan;4(1):88-98 [PMID: 25649429]
  28. Biomaterials. 2007 Dec;28(35):5344-57 [PMID: 17825905]
  29. Vet Res Commun. 2015 Dec;39(4):217-28 [PMID: 26395469]
  30. Front Immunol. 2019 Aug 20;10:1759 [PMID: 31481953]
  31. Hum Vaccin Immunother. 2018;14(11):2786-2801 [PMID: 29913109]
  32. Infect Immun. 2005 Dec;73(12):8079-88 [PMID: 16299302]
  33. Int J Nanomedicine. 2017 Dec 13;12:8769-8778 [PMID: 29263667]
  34. J Inorg Biochem. 2021 Jun;219:111454 [PMID: 33878530]
  35. Transbound Emerg Dis. 2022 Sep;69(5):e1253-e1268 [PMID: 35244335]
  36. Clin Exp Vaccine Res. 2021 Jan;10(1):35-43 [PMID: 33628752]
  37. APMIS. 2015 Aug;123(8):667-75 [PMID: 25939375]
  38. Avicenna J Phytomed. 2019 Mar-Apr;9(2):92-100 [PMID: 30984574]

Word Cloud

Created with Highcharts 10.0.0NPsCaPCaP/TBOIO/TBOphosphateoxideIOTBOprotectionCalciumironnanoparticlesdeliveryantigenvirulentimmune16MusingmodelproteinadministeredsubcutaneouslyshowedmiceadjuvantPurpose:promisingadjuvantssystemsvaccinationFurthermoreshownchimericTF/Bp26/Omp31goodcandidatestimulatingaimpresentstudycomparerolesinductionresponseMaterialsMethods:geneexpressedbacterialhostevaluatedSDS-PAGEwesternblotrecombinantloadedontoResults:AntibodylevelsimmunizationstimulatedmixedTh1-Th2responsesadditionimmunizedchallengedstrainImmunizedhigherdegreevaccinatedanimalsConclusion:AltogetherresultsindicatedpotentsystemantigenscomparisondeliveringfunctionscalciumBrucellosisIronNanoparticles

Similar Articles

Cited By

No available data.